Termedia.pl
 
 
ISSN: 1505-8409
Przewodnik Lekarza/Guide for GPs
Current issue Archive About the journal Supplements Contact Instructions for authors
6/2005
vol. 8
 
Share:
Share:
more
 
 
abstract:

Inhaled corticosteroids and long acting β2-agonists in asthma and chronic obstructive pulmonary disease (COPD)

Anna Doboszyńska

Przew Lek 2005; 6: 90-95
Online publish date: 2005/09/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Agonists of β2 receptors are the most potent bronchial dilators. Available long-acting β2-agonists are widely used in the treatment of both bronchial asthma and COPD. However, administration of these drugs alone is rather disadvantageous because of the risk of tachyphylaxis. Other group of medicines used in the bronchial asthma and COPD are inhaled glucorticosteroids. They are the first choice drugs in asthma therapy and their effectiveness is well documented. If, however, they are ineffective is the
administered dose, its increase does not bring about desired effect. In such a situation addition of the
long-acting β2-agonists accelerate stabilization of the disease course. Recently, several papers were
published, positively assessing the use of such a combined therapy in COPD. An effect of both
components are considered additive and not simply summed up.
keywords:

inhaled corticosteroids, long-acting β2-agonists, asthma, COPD

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe